Pharmaceuticals News

— Establishes QSYMIA as one of the most affordable branded weight-management options available in the United States — Effective immediately, uniform pricing across all four doses lowers QSYMIA’s...

WARRENDALE, Pa., Oct. 13, 2026 (GLOBE NEWSWIRE) -- ECM Therapeutics, Inc. today announced early clinical results suggesting its extracellular matrix (ECM) hydrogel, ECMT-100, could meaningfully...

NEW YORK and WALTHAM, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to...

October 13, 2026 Biodexa announces another Serenta milestone with 100 patients enrolled in its registrational Phase 3 trial in FAP Update on expected timing of pre-specified futility analysis and...

Randomized, placebo-controlled study to evaluate the safety, tolerability, and efficacy in a robust, two-part study First-in-class therapeutic targets Alveolar Epithelial Type 2 (AEC2) cells with the...

CAMBRIDGE, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to...

CARMEL, Ind. and BURLINGTON, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and...

SYDNEY, AUSTRALIA, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune...

Third drug candidate from Tenvie’s product engine to enter clinical development in 2026TNV313 joins TNV262 to give Tenvie two clinical-stage, fully CNS-penetrant NLRP3 inhibitors, enabling parallel...

Novastra Therapeutics to present initial clinical data for its first candidate in a novel category of cancer immune therapy at ESMO Congress 2026